American Journal of PharmTech Research

Nanotechnology-based medicines (nanomedicines) are emerging as a major innovation in the field of healthcare, combining nanoscale materials with pharmaceutical sciences to improve diagnosis, treatment, and prevention of diseases. This review explores the market potential and consumer acceptance of nanotechnology-based medicines. The nanomedicine market is expected to grow substantially due to increased prevalence of chronic diseases, advancements in targeted drug delivery, and rising investment in research and development.4 However, consumer acceptance is influenced by factors such as safety concerns, cost, ethical implications, and regulatory uncertainty. This paper highlights market dynamics, regional growth, challenges, and recommendations to improve acceptance and commercialization of nanomedicine. Despite these advancements, widespread consumer acceptance of nanomedicines remains influenced by several factors, including safety concerns, ethical considerations, high production costs, and lack of standardized regulatory frameworks. Public perception and awareness also play a critical role in determining market success. Furthermore, regional disparities in access to advanced healthcare technologies, limited infrastructure, and challenges in large-scale manufacturing hinder commercialization. This paper highlights current trends in nanomedicine development, market drivers, and barriers affecting its acceptance. It also discusses the potential impact of nanotechnology on personalized medicine and the pharmaceutical industry’s evolution. To enhance consumer trust and promote broader adoption, there is a need for transparent regulatory policies, ethical guidelines, and extensive clinical evaluation to ensure safety and efficacy. ed medicines hold the review concludes that with proper governance and technological refinement, nanotechnology-bas immense promise for transforming global healthcare systems.

Peptic ulcer disease (PUD) constitutes one of the most persistent gastroenterological disorders worldwide, with significant morbidity linked to gastric acid hypersecretion, oxidative stress, Helicobacter pylori infection, NSAID exposure, and compromised mucosal defensive integrity. Although numerous pharmacological options—including proton pump inhibitors, H? antagonists, prostaglandin analogues, and antibiotics—are available, their long-term utility remains constrained by adverse effects, recurrence, microbial resistance, and inadequate mucosal restitution. This has catalysed renewed scientific interest in botanicals with multifaceted gastroprotective actions. Trichosanthes dioica (Roxb.) leaves represent a phytochemically dense cucurbitaceous plant component historically utilized in Indian ethnomedicine for gastrointestinal, metabolic, hepatic, and inflammatory conditions. However, compared to fruits and roots, the leaves remain considerably under-investigated despite their rich flavonoid, phenolic, triterpenoid, saponin, and cucurbitacin profile. This review undertakes a rigorous pharmacognostic, phytochemical, mechanistic, and experimental examination of the gastroprotective potential of T. dioica leaves. Mechanistic emphasis is placed on antioxidant reinforcement, modulation of oxidative microenvironment, regulation of prostaglandin-mediated defence, inhibition of parietal proton pump activity, suppression of inflammatory cascades, stabilization of mast cells, modulation of nitric oxide bioavailability, and acceleration of epithelial restitution. The article aligns with the structural, stylistic, and referencing standards of the American Journal of PharmTech Research (AJPTR). The cumulative evidence demonstrates that T. dioica leaves exhibit significant gastroprotective effects, warranting their consideration as a promising phytopharmaceutical candidate for future antiulcer therapeutics.

Lasmiditan Hemisuccinate (LDT) is an innovative medication designed for the treatment of acute migraines, operating by activating 5-HT1F receptors found within the central nervous system. The synthesis of LDT necessitates the use of various solvents. According to regulatory standards, assessing the levels of residual solvents in drug substances is imperative in API (Active Pharmaceutical Ingredients). Present study concentrates on the evaluation and validation of a method for quantifying residual solvents like methanol, acetone, isopropyl alcohol, dichloromethane, methyl ter. butyl ether, n-hexane, ethyl acetate, n-heptane in LDT. Analysis was conducted using a DB-1 capillary column, measuring 60 meters in length with an internal diameter of 0.32 mm and a film thickness of 5 µ. The oven temperature was set to 65°C for 12 minutes, followed by a ramping rate of 15°C per minute to reach 85°C, where it was held for 5 minutes. Subsequently, a second ramping phase increased the temperature at a rate of 10°C per minute until it reached a final temperature of 220°C, which was maintained for 5 minutes. The injector temperature was maintained at 200°C and nitrogen was utilized as the carrier gas with 1-methyl-2-pyrrolidinone (NMP) diluent serving as the sample solvent. A suitable sensitive and robust HSGC-FID method is developed for quantitation of residual solvents with flame ionization (FID) detector. The evaluated method can applied to analyse of solvents present in a various range of APIs, intermediates.